论文部分内容阅读
目的探讨食管癌组织中KAI1/CD82、MRP1/CD9的表达及其临床意义。方法应用免疫组化SABC法检测54例食管癌组织中KAI1/CD82、MRP1/CD9的表达,并进行分析比较。结果食管癌组织KAI1/CD82的阳性表达率为61.5%(32/52)、MRP1/CD9的阳性表达率为57.4%(31/54)。两者的表达与淋巴结转移、肿瘤的分级、术后存活时间显著相关(P<0.05)。结论 KAI1/CD82、MRP1/CD9可作为食管癌的预后指标。
Objective To investigate the expression of KAI1 / CD82, MRP1 / CD9 in esophageal cancer and its clinical significance. Methods The expression of KAI1 / CD82 and MRP1 / CD9 in 54 cases of esophageal carcinoma was detected by immunohistochemical SABC method and analyzed. Results The positive expression rate of KAI1 / CD82 in esophageal carcinoma was 61.5% (32/52), and the positive rate of MRP1 / CD9 was 57.4% (31/54). The expression of them was significantly correlated with lymph node metastasis, tumor grade and postoperative survival time (P <0.05). Conclusions KAI1 / CD82 and MRP1 / CD9 can be used as prognostic indicators in esophageal cancer.